Long Ideas - With the approval of Kynamro, we believe that Isis Pharmaceuticals (NASDAQ:ISIS) is a compelling long-term investment due to it’s additional pipeline candidates, multiple drug development … Continue Reading
Long Ideas - InterMune (NASDAQ:ITMN) just announced very favorable pricing on their latest round of financing. The company sold $105 million aggregate principal amount of its 2.5% senior … Continue Reading
You're all done! We've sent you a confirmation email that includes a verification link. To access the page you're interested in, check your email inbox(including spam folder) and click the verification link.